A group of issues associated with inadequate nutrient intake is known as short bowel syndrome. People who have had at least half of their small intestine removed, as well as occasionally all or part of their large intestine, or who have substantial small intestine damage or poor intestinal motility, are more likely to develop short bowel syndrome. Depending on how well the small intestine is functioning, short bowel syndrome can range from mild to serious. People who have short bowel syndrome do not properly receive nutrients from their food, including water, vitamins, minerals, protein, fat, and calories.
The short bowel syndrome market is expanding at a CAGR of 14.7 % from 2023 to 2030 (forecast period).
Diarrhea is the main sign, and it can lead to starvation, dehydration, and weight loss. Bloating, heartburn, fatigue, lactose intolerance, and bad-smelling stool are some additional signs that may occur. Kidney stones and dehydration are examples of complications. particular diet, medicines, or surgery may be used as treatments. The diet may include short, frequent meals, vitamin and mineral supplements, slightly sweet and salty liquids, and an avoidance of foods rich in fat. Parenteral nutrition, or the administration of nourishment through an intravenous line, may occasionally be necessary. Antibiotics, antacids, loperamide, teduglutide, and growth hormone are just a few of the drugs that might be used. Some individuals may benefit from various surgical procedures, including intestinal transplants.
Short Bowel Syndrome Market to Recover Amid COVID-19 Pandemic
Numerous studies have demonstrated that the effects of the coronavirus on the digestive system can result in a variety of gastrointestinal problems. Angiotensin-converting enzyme 2 (ACE-2) in the intestine is where the SARS-CoV-2 virus attaches, impacting the digestive system. According to information provided by UpToDate, Inc., one-third of COVID-19 patients who were severely ill in 2021 were thought to have experienced gastrointestinal problems. Along with several other gastrointestinal diseases, the SARS-CoV-2 infection led to a number of complications, including inflammatory bowel disease and other gastrointestinal tract infections. Additionally, COVID-19 impacted people who had severe inflammatory bowel disease, which led to a rise in Crohn’s disease cases because of weakened immune systems. Due to lengthy hospital stays and other problems related to parenteral nutrition therapy, it was not widely used during the pandemic. Due to this, there is now a greater market desire for medications based on GLP-2. These elements collectively contributed to the market’s expansion.
Increasing Prevalence of GI disorders to Boost Short Bowel Syndrome Market
The major factors attributing to the growth of the SBS market are the increased prevalence of GI disorders such as volvulus, Inflammatory bowel disease (IBD), Crohn’s disease (CD), and mesenteric ischemia, rising awareness by non-profit organizations, and rising initiatives from the key players in the launch of key products, among others.
According to a study that was published in Surgery Today in January 2021, SBS is predicted to affect 24.5 out of every 100,000 live births, and before selecting from the various nutritional, pharmaceutical, and surgical treatment options, a thorough evaluation is required. As a result of the widespread use of therapies to treat the condition, the high prevalence of SBS is anticipated to spur market expansion. Over the course of the forecast period, market growth is anticipated to be fueled by the growing efforts taken by market participants in the development of therapies for SBS. For instance, the clinical-stage company 9 Meters Biopharma published encouraging topline findings from the phase II study of VurolenatIde for SBS in June 2022. As a result, the market participants’ increased research efforts will result in the creation of new SBS therapies, which will boost adoption and fuel market growth.
Therefore, it is anticipated that growing launches of therapies for SBS and rising prevalence of GI disorders will propel market development.
North America to Spearhead the Short Bowel Syndrome Market
North America is the fastest-growing segment in the short bowel syndrome market due to several factors, including:
- Rising prevalence of SBS: Increasing incidences of short bowel syndrome in North America is fueling the market for short bowel syndrome in this region. In the United States, there are approximately 120 home parenteral nutrition cases per million people each year, with SBS accounting for about 25% of cases, according to a study released in UpToDate in November 2021. Due to the increased use of SBS treatments in the country, the market is anticipated to expand as a result of the high prevalence of SBS there.
- Increasing Investment in Healthcare: Governments and private organizations in North America are investing heavily in healthcare infrastructure and research and development. This investment is driving innovation and the development of new therapies for a range of diseases.
- Increased sedentary life: The increase in sedentary lifestyles has made it harder to prioritize eating wholesome foods, leading to an increase in the consumption of unhealthy and junk food and the ensuing intestinal diseases, which is a major factor driving market growth in the region.
- Rising funding for research: Increase in grants from government bodies is responsible for the large share of the North American short bowel syndrome market. For instance, a researcher at Saint Louis University School of Medicine (SBS) received financing of USD 1.9 million in October 2021 to study SBS.
Companies operating in the short bowel syndrome market have adopted several growth strategies to expand their market share and increase their revenue. Some of the key players in the short bowel syndrome market are Takeda Pharmaceutical Company Limited, Merck KGaA, Zealand Pharma A/S, OxThera, VectivBio AG, 9 Meters Biopharma, Inc., Nutrinia Ltd., Hanmi Pharm.Co., Ltd., Pharmascience, Inc., Johnsons & Johnsons Services Inc , Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Sanofi , GSK Plc., Novartis AG, Pfizer Inc., Amneal Pharmaceuticals LLC. , Alvogen , and Hikma Pharmaceuticals PLC
- Partnerships and Collaborations: Companies are forming partnerships and collaborations to share expertise and resources to accelerate the development of new short bowel syndrome drugs. These partnerships enable companies to leverage their strengths and develop new therapies more efficiently.
- Product Development and Launches: Companies are investing in research and development to develop new short bowel syndrome drugs and improve existing products. These companies are launching new products in the market to expand their product portfolios and gain a competitive advantage.
- Geographical Expansion: Companies are expanding their geographical presence by entering new markets and establishing a presence in regions with high growth potential. This enables companies to tap into new customer bases and increase their revenue. Nestlé Health Science invested USD 50.0 million in July 2020 to the construction of a manufacturing facility in the United States that produces infant formula and medical nutrition goods like peptamen. The distribution of the goods in Canada, Brazil, Mexico, Australia, and Taiwan is another goal of this venture.
- Acquisitions and Mergers: Companies are acquiring or merging with other companies to gain access to new technologies, expertise, and product pipelines. These acquisitions and mergers enable companies to expand their capabilities and product offerings and increase their market share. By changing its name from Innovate Biopharmaceuticals, Inc. to 9 Meters Biopharma, Inc. on April 30, 2020, 9 Meters Biopharma, Inc. completed its merger with privately owned RDD Pharma, Ltd., an Israeli company (“RDD”). By completing the acquisition of Shire plc in January 2019, Takeda Pharmaceutical Company Limited transformed into a leading biopharmaceutical company with a worldwide focus on values-based R&D
- Marketing and Promotional Activities: Companies are investing in marketing and promotional activities to increase awareness and educate healthcare professionals and patients about the benefits of short bowel syndrome drugs. This enables companies to increase demand for their products and drive sales.
Overall, these growth strategies enable companies to expand their market presence, develop new products, and increase their revenue in the short bowel syndrome market